5/20
08:42 am
lixt
LIXTE Biotechnology Holdings Provides Update on Recent Activities [Yahoo! Finance]
Low
Report
LIXTE Biotechnology Holdings Provides Update on Recent Activities [Yahoo! Finance]
5/20
08:30 am
lixt
LIXTE Biotechnology Holdings Provides Update on Recent Activities
Low
Report
LIXTE Biotechnology Holdings Provides Update on Recent Activities
5/8
09:28 am
lixt
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” [Yahoo! Finance]
Low
Report
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” [Yahoo! Finance]
5/8
09:25 am
lixt
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Low
Report
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
3/27
01:24 pm
lixt
SMR, GCTS and GSIW among mid-day movers [Seeking Alpha]
Medium
Report
SMR, GCTS and GSIW among mid-day movers [Seeking Alpha]
3/27
08:33 am
lixt
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES [Yahoo! Finance]
Medium
Report
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES [Yahoo! Finance]
3/27
08:30 am
lixt
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
High
Report
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
3/21
08:38 am
lixt
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments [Yahoo! Finance]
Medium
Report
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments [Yahoo! Finance]
3/21
08:30 am
lixt
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Medium
Report
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments